Closure Medical adopts rights plan:
This article was originally published in Clinica
Executive Summary
Closure Medical, which develops and manufactures adhesive products based on its proprietary cyanoacrylate technology for wound closure, has put in place a shareholder rights plan. The plan is activated if a third party acquires 15% or more of the company or announces a tender amount for that amount. "We believe that the plan protects stockholder interests in the event that the company is confronted with coercive or unfair takeover tactics, including offers that do not treat all stockholder interests fairly or do not maximise the value of the company," said Robert Toni, president and CEO of the Raleigh, North Carolina-based company.
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.